Atrys is a biomedical company dedicated to provide diagnostic services and excelence medical treatments. It aims is to facilitate patients with individualized therapy, as well as to develop new therapeutic modalities and diagnostic tools.
The company was founded in 2007 by a group of doctors and cancer experts led by Dr. Carlos Cordon-Cardo, with the aim of providing a new model in the clinical management of cancer, by combining innovative and precise diagnostic techniques surgical and molecular pathology, along with new radiotherapy treatments.
Within the diagnostics business other than in the area of oncology, Atrys uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology and dermatology, using its own technology platform. This activity benefits Atrys's business relationship with stakeholders in the health sector, in a simmilar manner as in the field of oncology.
Research conducted by the team of Atrys in collaboration with international medical centers of academic excellence has produced results indicating that Single Dose high intensity radiation treatments allow to activate different biological mechanisms for tumor cure that are not activated with conventional radiotherapy.
The company model includes a molecular diagnostic methodology for individual tumor phenotyping that generates information that allows the specialist to identify which clinical approach is more appropriate for each patient and, in particular, to identify those who can benefit from the single-dose stereotactic body radiation therapy (SD-SBRT or Single dose radiotherapy).